Compounds > ucb 35625
Page last updated: 2024-11-08

ucb 35625

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

UCB 35625: J-113863 is the (trans)-isomer; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6918496
CHEMBL ID277930
CHEMBL ID34626
SCHEMBL ID8187807
SCHEMBL ID8189438
SCHEMBL ID8184177
MeSH IDM0369998

Synonyms (38)

Synonym
j-113863
ucb 35625
j 113863
CHEMBL277930 ,
chembl34626
1,4-trans-1-(1-cycloocten-1-ylmethyl)-4-[[(2,7-dichloro-9h-xanthen-9-yl)carbonyl]amino]-1-ethylpiperidinium iodide
353791-85-2
piperidinium, 1-(1-cycloocten-1-ylmethyl)-4-(((2,7-dichloro-9h-xanthen-9-yl)carbonyl)amino)-1-ethyl-, iodide (1:1), trans-
HD099HOT7H ,
j-113863, trans-
342807-82-3
piperidinium, 1-(1-cycloocten-1-ylmethyl)-4-(((2,7-dichloro-9h-xanthen-9-yl)carbonyl)amino)-1-ethyl-, iodide, trans-
j-113863, cis-
piperidinium, 1-(1-cycloocten-1-ylmethyl)-4-(((2,7-dichloro-9h-xanthen-9-yl)carbonyl)amino)-1-ethyl-, iodide, cis-
H942HGF14D ,
342807-83-4
piperidinium, 1-(1-cycloocten-1-ylmethyl)-4-(((2,7-dichloro-9h-xanthen-9-yl)carbonyl)amino)-1-ethyl-, iodide (1:1), cis-
AKOS025295214
unii-h942hgf14d
unii-hd099hot7h
202796-42-7
202796-41-6
SCHEMBL8187807
SCHEMBL8189438
SCHEMBL8184177
1,4-cis-1-(1-cycloocten-1-ylmethyl)-4-[[(2,7-dichloro-9h-xanthen-9-yl)carbonyl]amino]-1-ethylpiperidinium iodide
J-017805
301648-08-8
HY-103360
CS-0027742
Q27279862
trans-j-113863
Q27279784
cis-j-113863
2,7-dichloro-n-[1-[[(1e)-cycloocten-1-yl]methyl]-1-ethylpiperidin-1-ium-4-yl]-9h-xanthene-9-carboxamide;iodide
F81765
MS-30985
AKOS040733478
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (8)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
C-C chemokine receptor type 1Homo sapiens (human)IC50 (µMol)0.01010.00070.20022.5000AID223365; AID223366; AID43205
Corticotropin-releasing factor receptor 1Homo sapiens (human)IC50 (µMol)5.00040.00070.06490.3400AID223366; AID223370
C-C chemokine receptor type 2Homo sapiens (human)IC50 (µMol)1.00000.00000.67366.6990AID223367
C-C chemokine receptor type 1Mus musculus (house mouse)IC50 (µMol)0.15690.00580.91425.0000AID221354; AID221355; AID221356
C-C chemokine receptor type 3Homo sapiens (human)IC50 (µMol)0.00240.00060.60419.0000AID223368; AID223369; AID43229
Probable C-C chemokine receptor type 3Mus musculus (house mouse)IC50 (µMol)0.40500.35000.40500.4600AID221357; AID221358
C-C chemokine receptor type 4Homo sapiens (human)IC50 (µMol)10.00000.20004.542410.0000AID223370
C-C chemokine receptor type 5Homo sapiens (human)IC50 (µMol)1.00000.00020.25679.0000AID42494
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (96)

Processvia Protein(s)Taxonomy
dendritic cell chemotaxisC-C chemokine receptor type 1Homo sapiens (human)
monocyte chemotaxisC-C chemokine receptor type 1Homo sapiens (human)
calcium ion transportC-C chemokine receptor type 1Homo sapiens (human)
intracellular calcium ion homeostasisC-C chemokine receptor type 1Homo sapiens (human)
exocytosisC-C chemokine receptor type 1Homo sapiens (human)
chemotaxisC-C chemokine receptor type 1Homo sapiens (human)
immune responseC-C chemokine receptor type 1Homo sapiens (human)
cell adhesionC-C chemokine receptor type 1Homo sapiens (human)
cell surface receptor signaling pathwayC-C chemokine receptor type 1Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerC-C chemokine receptor type 1Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationC-C chemokine receptor type 1Homo sapiens (human)
cell-cell signalingC-C chemokine receptor type 1Homo sapiens (human)
response to woundingC-C chemokine receptor type 1Homo sapiens (human)
negative regulation of gene expressionC-C chemokine receptor type 1Homo sapiens (human)
cytokine-mediated signaling pathwayC-C chemokine receptor type 1Homo sapiens (human)
positive regulation of cell migrationC-C chemokine receptor type 1Homo sapiens (human)
negative regulation of bone mineralizationC-C chemokine receptor type 1Homo sapiens (human)
positive regulation of osteoclast differentiationC-C chemokine receptor type 1Homo sapiens (human)
positive regulation of calcium ion transportC-C chemokine receptor type 1Homo sapiens (human)
chemokine-mediated signaling pathwayC-C chemokine receptor type 1Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeC-C chemokine receptor type 1Homo sapiens (human)
positive regulation of monocyte chemotaxisC-C chemokine receptor type 1Homo sapiens (human)
calcium-mediated signalingC-C chemokine receptor type 1Homo sapiens (human)
cell chemotaxisC-C chemokine receptor type 1Homo sapiens (human)
inflammatory responseC-C chemokine receptor type 1Homo sapiens (human)
immune responseCorticotropin-releasing factor receptor 1Homo sapiens (human)
cell surface receptor signaling pathwayCorticotropin-releasing factor receptor 1Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayCorticotropin-releasing factor receptor 1Homo sapiens (human)
activation of adenylate cyclase activityCorticotropin-releasing factor receptor 1Homo sapiens (human)
female pregnancyCorticotropin-releasing factor receptor 1Homo sapiens (human)
parturitionCorticotropin-releasing factor receptor 1Homo sapiens (human)
regulation of adenylate cyclase activity involved in G protein-coupled receptor signaling pathwayCorticotropin-releasing factor receptor 1Homo sapiens (human)
adrenal gland developmentCorticotropin-releasing factor receptor 1Homo sapiens (human)
exploration behaviorCorticotropin-releasing factor receptor 1Homo sapiens (human)
fear responseCorticotropin-releasing factor receptor 1Homo sapiens (human)
behavioral response to ethanolCorticotropin-releasing factor receptor 1Homo sapiens (human)
corticotropin secretionCorticotropin-releasing factor receptor 1Homo sapiens (human)
general adaptation syndrome, behavioral processCorticotropin-releasing factor receptor 1Homo sapiens (human)
cellular response to corticotropin-releasing hormone stimulusCorticotropin-releasing factor receptor 1Homo sapiens (human)
negative regulation of voltage-gated calcium channel activityCorticotropin-releasing factor receptor 1Homo sapiens (human)
regulation of corticosterone secretionCorticotropin-releasing factor receptor 1Homo sapiens (human)
cytokine-mediated signaling pathwayC-C chemokine receptor type 2Homo sapiens (human)
blood vessel remodelingC-C chemokine receptor type 2Homo sapiens (human)
dendritic cell chemotaxisC-C chemokine receptor type 2Homo sapiens (human)
monocyte chemotaxisC-C chemokine receptor type 2Homo sapiens (human)
regulation of T cell cytokine productionC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of T-helper 1 type immune responseC-C chemokine receptor type 2Homo sapiens (human)
negative regulation of type 2 immune responseC-C chemokine receptor type 2Homo sapiens (human)
intracellular calcium ion homeostasisC-C chemokine receptor type 2Homo sapiens (human)
chemotaxisC-C chemokine receptor type 2Homo sapiens (human)
humoral immune responseC-C chemokine receptor type 2Homo sapiens (human)
cellular defense responseC-C chemokine receptor type 2Homo sapiens (human)
negative regulation of adenylate cyclase activityC-C chemokine receptor type 2Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATC-C chemokine receptor type 2Homo sapiens (human)
response to woundingC-C chemokine receptor type 2Homo sapiens (human)
regulation of vascular endothelial growth factor productionC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of T cell chemotaxisC-C chemokine receptor type 2Homo sapiens (human)
negative regulation of angiogenesisC-C chemokine receptor type 2Homo sapiens (human)
sensory perception of painC-C chemokine receptor type 2Homo sapiens (human)
cellular homeostasisC-C chemokine receptor type 2Homo sapiens (human)
hemopoiesisC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of type II interferon productionC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of interleukin-2 productionC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of tumor necrosis factor productionC-C chemokine receptor type 2Homo sapiens (human)
monocyte extravasationC-C chemokine receptor type 2Homo sapiens (human)
T-helper 17 cell chemotaxisC-C chemokine receptor type 2Homo sapiens (human)
negative regulation of eosinophil degranulationC-C chemokine receptor type 2Homo sapiens (human)
regulation of T cell differentiationC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of alpha-beta T cell proliferationC-C chemokine receptor type 2Homo sapiens (human)
homeostasis of number of cells within a tissueC-C chemokine receptor type 2Homo sapiens (human)
regulation of inflammatory responseC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of inflammatory responseC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of T cell activationC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicC-C chemokine receptor type 2Homo sapiens (human)
leukocyte adhesion to vascular endothelial cellC-C chemokine receptor type 2Homo sapiens (human)
chemokine-mediated signaling pathwayC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of monocyte chemotaxisC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of immune complex clearance by monocytes and macrophagesC-C chemokine receptor type 2Homo sapiens (human)
inflammatory response to woundingC-C chemokine receptor type 2Homo sapiens (human)
neutrophil clearanceC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of cold-induced thermogenesisC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of leukocyte tethering or rollingC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of NMDA glutamate receptor activityC-C chemokine receptor type 2Homo sapiens (human)
macrophage migrationC-C chemokine receptor type 2Homo sapiens (human)
regulation of macrophage migrationC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of thymocyte migrationC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of monocyte extravasationC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of CD8-positive, alpha-beta T cell extravasationC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of astrocyte chemotaxisC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of hematopoietic stem cell migrationC-C chemokine receptor type 2Homo sapiens (human)
cell chemotaxisC-C chemokine receptor type 2Homo sapiens (human)
calcium-mediated signalingC-C chemokine receptor type 2Homo sapiens (human)
inflammatory responseC-C chemokine receptor type 2Homo sapiens (human)
immune responseC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationC-C chemokine receptor type 2Homo sapiens (human)
positive regulation of endothelial cell proliferationC-C chemokine receptor type 3Homo sapiens (human)
chemotaxisC-C chemokine receptor type 3Homo sapiens (human)
cellular defense responseC-C chemokine receptor type 3Homo sapiens (human)
cell adhesionC-C chemokine receptor type 3Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayC-C chemokine receptor type 3Homo sapiens (human)
positive regulation of angiogenesisC-C chemokine receptor type 3Homo sapiens (human)
chemokine-mediated signaling pathwayC-C chemokine receptor type 3Homo sapiens (human)
calcium-mediated signalingC-C chemokine receptor type 3Homo sapiens (human)
inflammatory responseC-C chemokine receptor type 3Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationC-C chemokine receptor type 3Homo sapiens (human)
immune responseC-C chemokine receptor type 3Homo sapiens (human)
cell chemotaxisC-C chemokine receptor type 3Homo sapiens (human)
tolerance inductionC-C chemokine receptor type 4Homo sapiens (human)
chemotaxisC-C chemokine receptor type 4Homo sapiens (human)
inflammatory responseC-C chemokine receptor type 4Homo sapiens (human)
response to bacteriumC-C chemokine receptor type 4Homo sapiens (human)
homeostasis of number of cellsC-C chemokine receptor type 4Homo sapiens (human)
positive regulation of positive chemotaxisC-C chemokine receptor type 4Homo sapiens (human)
chemokine-mediated signaling pathwayC-C chemokine receptor type 4Homo sapiens (human)
interneuron migrationC-C chemokine receptor type 4Homo sapiens (human)
cell chemotaxisC-C chemokine receptor type 4Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationC-C chemokine receptor type 4Homo sapiens (human)
immune responseC-C chemokine receptor type 4Homo sapiens (human)
calcium-mediated signalingC-C chemokine receptor type 4Homo sapiens (human)
MAPK cascadeC-C chemokine receptor type 5Homo sapiens (human)
dendritic cell chemotaxisC-C chemokine receptor type 5Homo sapiens (human)
calcium ion transportC-C chemokine receptor type 5Homo sapiens (human)
chemotaxisC-C chemokine receptor type 5Homo sapiens (human)
cellular defense responseC-C chemokine receptor type 5Homo sapiens (human)
cell surface receptor signaling pathwayC-C chemokine receptor type 5Homo sapiens (human)
G protein-coupled receptor signaling pathwayC-C chemokine receptor type 5Homo sapiens (human)
cell-cell signalingC-C chemokine receptor type 5Homo sapiens (human)
release of sequestered calcium ion into cytosol by sarcoplasmic reticulumC-C chemokine receptor type 5Homo sapiens (human)
calcium-mediated signalingC-C chemokine receptor type 5Homo sapiens (human)
signalingC-C chemokine receptor type 5Homo sapiens (human)
symbiont entry into host cellC-C chemokine receptor type 5Homo sapiens (human)
chemokine-mediated signaling pathwayC-C chemokine receptor type 5Homo sapiens (human)
response to cholesterolC-C chemokine receptor type 5Homo sapiens (human)
cellular response to lipopolysaccharideC-C chemokine receptor type 5Homo sapiens (human)
negative regulation of macrophage apoptotic processC-C chemokine receptor type 5Homo sapiens (human)
inflammatory responseC-C chemokine receptor type 5Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationC-C chemokine receptor type 5Homo sapiens (human)
immune responseC-C chemokine receptor type 5Homo sapiens (human)
cell chemotaxisC-C chemokine receptor type 5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (18)

Processvia Protein(s)Taxonomy
phosphatidylinositol phospholipase C activityC-C chemokine receptor type 1Homo sapiens (human)
chemokine receptor activityC-C chemokine receptor type 1Homo sapiens (human)
protein bindingC-C chemokine receptor type 1Homo sapiens (human)
C-C chemokine receptor activityC-C chemokine receptor type 1Homo sapiens (human)
C-C chemokine bindingC-C chemokine receptor type 1Homo sapiens (human)
chemokine (C-C motif) ligand 7 bindingC-C chemokine receptor type 1Homo sapiens (human)
chemokine (C-C motif) ligand 5 bindingC-C chemokine receptor type 1Homo sapiens (human)
protein bindingCorticotropin-releasing factor receptor 1Homo sapiens (human)
corticotrophin-releasing factor receptor activityCorticotropin-releasing factor receptor 1Homo sapiens (human)
G protein-coupled peptide receptor activityCorticotropin-releasing factor receptor 1Homo sapiens (human)
corticotropin-releasing hormone bindingCorticotropin-releasing factor receptor 1Homo sapiens (human)
corticotropin-releasing hormone receptor activityCorticotropin-releasing factor receptor 1Homo sapiens (human)
chemokine receptor activityC-C chemokine receptor type 2Homo sapiens (human)
protein bindingC-C chemokine receptor type 2Homo sapiens (human)
CCR2 chemokine receptor bindingC-C chemokine receptor type 2Homo sapiens (human)
chemokine (C-C motif) ligand 2 bindingC-C chemokine receptor type 2Homo sapiens (human)
chemokine (C-C motif) ligand 12 bindingC-C chemokine receptor type 2Homo sapiens (human)
chemokine (C-C motif) ligand 7 bindingC-C chemokine receptor type 2Homo sapiens (human)
identical protein bindingC-C chemokine receptor type 2Homo sapiens (human)
C-C chemokine bindingC-C chemokine receptor type 2Homo sapiens (human)
C-C chemokine receptor activityC-C chemokine receptor type 2Homo sapiens (human)
chemokine receptor activityC-C chemokine receptor type 3Homo sapiens (human)
protein bindingC-C chemokine receptor type 3Homo sapiens (human)
C-C chemokine bindingC-C chemokine receptor type 3Homo sapiens (human)
C-C chemokine receptor activityC-C chemokine receptor type 3Homo sapiens (human)
chemokine receptor activityC-C chemokine receptor type 4Homo sapiens (human)
protein bindingC-C chemokine receptor type 4Homo sapiens (human)
C-C chemokine receptor activityC-C chemokine receptor type 4Homo sapiens (human)
C-C chemokine bindingC-C chemokine receptor type 4Homo sapiens (human)
virus receptor activityC-C chemokine receptor type 5Homo sapiens (human)
actin bindingC-C chemokine receptor type 5Homo sapiens (human)
phosphatidylinositol phospholipase C activityC-C chemokine receptor type 5Homo sapiens (human)
chemokine receptor activityC-C chemokine receptor type 5Homo sapiens (human)
protein bindingC-C chemokine receptor type 5Homo sapiens (human)
coreceptor activityC-C chemokine receptor type 5Homo sapiens (human)
C-C chemokine receptor activityC-C chemokine receptor type 5Homo sapiens (human)
C-C chemokine bindingC-C chemokine receptor type 5Homo sapiens (human)
identical protein bindingC-C chemokine receptor type 5Homo sapiens (human)
chemokine (C-C motif) ligand 5 bindingC-C chemokine receptor type 5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
plasma membraneC-C chemokine receptor type 1Homo sapiens (human)
external side of plasma membraneC-C chemokine receptor type 1Homo sapiens (human)
external side of plasma membraneC-C chemokine receptor type 1Homo sapiens (human)
cytoplasmC-C chemokine receptor type 1Homo sapiens (human)
endosomeCorticotropin-releasing factor receptor 1Homo sapiens (human)
plasma membraneCorticotropin-releasing factor receptor 1Homo sapiens (human)
membraneCorticotropin-releasing factor receptor 1Homo sapiens (human)
plasma membraneCorticotropin-releasing factor receptor 1Homo sapiens (human)
neuron projectionCorticotropin-releasing factor receptor 1Homo sapiens (human)
fibrillar centerC-C chemokine receptor type 2Homo sapiens (human)
cytoplasmC-C chemokine receptor type 2Homo sapiens (human)
cytosolC-C chemokine receptor type 2Homo sapiens (human)
plasma membraneC-C chemokine receptor type 2Homo sapiens (human)
membraneC-C chemokine receptor type 2Homo sapiens (human)
dendriteC-C chemokine receptor type 2Homo sapiens (human)
neuronal cell bodyC-C chemokine receptor type 2Homo sapiens (human)
perikaryonC-C chemokine receptor type 2Homo sapiens (human)
perinuclear region of cytoplasmC-C chemokine receptor type 2Homo sapiens (human)
cytoplasmC-C chemokine receptor type 2Homo sapiens (human)
external side of plasma membraneC-C chemokine receptor type 2Homo sapiens (human)
plasma membraneC-C chemokine receptor type 3Homo sapiens (human)
external side of plasma membraneC-C chemokine receptor type 3Homo sapiens (human)
cytoplasmC-C chemokine receptor type 3Homo sapiens (human)
plasma membraneC-C chemokine receptor type 4Homo sapiens (human)
neuronal cell bodyC-C chemokine receptor type 4Homo sapiens (human)
external side of plasma membraneC-C chemokine receptor type 4Homo sapiens (human)
cell surfaceC-C chemokine receptor type 5Homo sapiens (human)
endosomeC-C chemokine receptor type 5Homo sapiens (human)
plasma membraneC-C chemokine receptor type 5Homo sapiens (human)
external side of plasma membraneC-C chemokine receptor type 5Homo sapiens (human)
cell surfaceC-C chemokine receptor type 5Homo sapiens (human)
external side of plasma membraneC-C chemokine receptor type 5Homo sapiens (human)
cytoplasmC-C chemokine receptor type 5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID223370Inhibitory activity against Taer induced increase in intracellular [Ca2+] in KU812 cells expressing human CCR4 receptor2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Design, synthesis, and discovery of a novel CCR1 antagonist.
AID43229Concentration required for 50% inhibition of [125I]eotaxin binding to human CCR3 receptor expressed in CHO cells2001Bioorganic & medicinal chemistry letters, May-07, Volume: 11, Issue:9
Discovery of a novel CCR3 selective antagonist.
AID221358Inhibitory activity against I-Eotaxin induced [Ca2+] response in mouse CCR3 receptor2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Design, synthesis, and discovery of a novel CCR1 antagonist.
AID223367Inhibitory activity in human CCR2b receptor2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Design, synthesis, and discovery of a novel CCR1 antagonist.
AID221357Inhibitory activity against I-Eotaxin alpha binding to mouse CCR3 receptors2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Design, synthesis, and discovery of a novel CCR1 antagonist.
AID223373Inhibitory activity of Fractalkine-induced increase in [Ca2+] Conc. in HEL cells at human CX3CR1 receptor2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Design, synthesis, and discovery of a novel CCR1 antagonist.
AID223365Inhibitory activity against [125I]-MIP-1 alpha binding to human CCR1 receptors.2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Design, synthesis, and discovery of a novel CCR1 antagonist.
AID223369Inhibitory activity against I-Eotaxin induced [Ca2+] response in human CCR3 receptor2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Design, synthesis, and discovery of a novel CCR1 antagonist.
AID42494Inhibition of RANTES binding to C-C chemokine receptor type 52001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Design, synthesis, and discovery of a novel CCR1 antagonist.
AID223366Inhibitory activity against MIP-1 alpha- induced [Ca2+] response in U937 cells expressing human CCR1 receptor2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Design, synthesis, and discovery of a novel CCR1 antagonist.
AID221354Inhibitory activity against 125 I -MIP-1 alpha binding to mouse CCR1 receptors2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Design, synthesis, and discovery of a novel CCR1 antagonist.
AID43205Concentration required for 50% inhibition of [125I]eotaxin binding to human CCR1 receptor expressed in CHO cells2001Bioorganic & medicinal chemistry letters, May-07, Volume: 11, Issue:9
Discovery of a novel CCR3 selective antagonist.
AID221355Inhibitory activity against [125I]-MIP-1 alpha binding to mouse CCR1 receptors.2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Design, synthesis, and discovery of a novel CCR1 antagonist.
AID221356inhibitory activity against MIP-1 alpha- induced [Ca2+] response in U937 cells expressing mouse CCR1 receptor2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Design, synthesis, and discovery of a novel CCR1 antagonist.
AID223368Inhibitory activity against I-Eotaxin binding to human CCR3 receptors2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Design, synthesis, and discovery of a novel CCR1 antagonist.
AID223374Inhibitory activity of I-interleukin-8-binding to human neutrophil at human CXCR1,2 receptor2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Design, synthesis, and discovery of a novel CCR1 antagonist.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (46.15)29.6817
2010's6 (46.15)24.3611
2020's1 (7.69)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
tyrosine
Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring.		2.0310amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
tyrosine		EC 1.3.1.43 (arogenate dehydrogenase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical
phenylalanine
Phenylalanine: An essential aromatic amino acid that is a precursor of MELANIN; DOPAMINE; noradrenalin (NOREPINEPHRINE), and THYROXINE.. L-phenylalanine : The L-enantiomer of phenylalanine.. phenylalanine : An aromatic amino acid that is alanine in which one of the methyl hydrogens is substituted by a phenyl group.		2.0810amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
phenylalanine;
proteinogenic amino acid		algal metabolite;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
Escherichia coli metabolite;
human xenobiotic metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
xanthenes
Xanthenes: Compounds with three aromatic rings in linear arrangement with an OXYGEN in the center ring.		3.86110xanthene
glutamic acid
Glutamic Acid: A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM.. glutamic acid : An alpha-amino acid that is glutaric acid bearing a single amino substituent at position 2.		2.4320glutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical
buprenorphine
Buprenorphine: A derivative of the opioid alkaloid THEBAINE that is a more potent and longer lasting analgesic than MORPHINE. It appears to act as a partial agonist at mu and kappa opioid receptors and as an antagonist at delta receptors. The lack of delta-agonist activity has been suggested to account for the observation that buprenorphine tolerance may not develop with chronic use.. buprenorphine : A morphinane alkaloid that is 7,8-dihydromorphine 6-O-methyl ether in which positions 6 and 14 are joined by a -CH2CH2- bridge, one of the hydrogens of the N-methyl group is substituted by cyclopropyl, and a hydrogen at position 7 is substituted by a 2-hydroxy-3,3-dimethylbutan-2-yl group. It is highly effective for the treatment of opioid use disorder and is also increasingly being used in the treatment of chronic pain.		2.2510morphinane alkaloiddelta-opioid receptor antagonist;
kappa-opioid receptor antagonist;
mu-opioid receptor agonist;
opioid analgesic
peptide t amide
peptide T amide: octapeptide segment of HIV envelope gp120; used in AIDS therapy		2.110
morphine
Meconium: The thick green-to-black mucilaginous material found in the intestines of a full-term fetus. It consists of secretions of the INTESTINAL GLANDS; BILE PIGMENTS; FATTY ACIDS; AMNIOTIC FLUID; and intrauterine debris. It constitutes the first stools passed by a newborn.		2.2510morphinane alkaloid;
organic heteropentacyclic compound;
tertiary amino compound		anaesthetic;
drug allergen;
environmental contaminant;
geroprotector;
mu-opioid receptor agonist;
opioid analgesic;
plant metabolite;
vasodilator agent;
xenobiotic
5-oxo-6,8,11,14-eicosatetraenoic acid
5-oxo-6,8,11,14-eicosatetraenoic acid: RN given is for cpd without isomeric designation; an arachidonate metabolite which stimulates neutrophils to mobilize Ca and promotes PMN degranulation responses		2.0810
sb 297006
SB 297006: a CC chemokine receptor-3 antagonist that inhibits binding of eotaxin and monocyte chemotactic protein-4 to eosinophils; structure in first source		2.0810
mocetinostat
mocetinostat: undergoing phase II clinical trials for treatment of cancer. mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11).		2.2510aminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline		antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent
vuf 2274
5-(4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl)-2,2-diphenylpentanenitrile: an inverse agonist of human cytomegalovirus; structure in first source		210
sb 328437
SB 328437: a CC chemokine receptor-3 antagonist that inhibits binding of eotaxin and monocyte chemotactic protein-4 to eosinophils; structure in first source		2.0810
peptide t
Peptide T: N-(N-(N(2)-(N-(N-(N-(N-D-Alanyl L-seryl)-L-threonyl)-L-threonyl) L-threonyl)-L-asparaginyl)-L-tyrosyl) L-threonine. Octapeptide sharing sequence homology with HIV envelope protein gp120. It is potentially useful as antiviral agent in AIDS therapy. The core pentapeptide sequence, TTNYT, consisting of amino acids 4-8 in peptide T, is the HIV envelope sequence required for attachment to the CD4 receptor.		2.110
ConditionIndicatedRelationship StrengthStudiesTrials
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		03.0640
Allodynia
[description not available]		02.8330
Nerve Pain
[description not available]		02.6120
Neuralgia
Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.		02.6120
Alloxan Diabetes
[description not available]		02.1710
Asymmetric Diabetic Proximal Motor Neuropathy
[description not available]		02.1710
Diabetic Neuropathies
Peripheral, autonomic, and cranial nerve disorders that are associated with DIABETES MELLITUS. These conditions usually result from diabetic microvascular injury involving small blood vessels that supply nerves (VASA NERVORUM). Relatively common conditions which may be associated with diabetic neuropathy include third nerve palsy (see OCULOMOTOR NERVE DISEASES); MONONEUROPATHY; mononeuropathy multiplex; diabetic amyotrophy; a painful POLYNEUROPATHY; autonomic neuropathy; and thoracoabdominal neuropathy. (From Adams et al., Principles of Neurology, 6th ed, p1325)		02.1710
Asthma, Bronchial
[description not available]		02.0810
Asthma
A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).		02.0810
Bone Cancer
[description not available]		02.110
Bone Neoplasms
Tumors or cancer located in bone tissue or specific BONES.		02.110
Pain, Chronic
[description not available]		02.1310
Innate Inflammatory Response
[description not available]		02.4620
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.4620
Chronic Pain
Aching sensation that persists for more than a few months. It may or may not be associated with trauma or disease, and may persist after the initial injury has healed. Its localization, character, and timing are more vague than with acute pain.		02.1310
Acute Pain
Intensely discomforting, distressful, or agonizing sensation associated with trauma or disease, with well-defined location, character, and timing.		02.1310
Osteolysis
Dissolution of bone that particularly involves the removal or loss of calcium.		02.0710
Prosthesis Durability
[description not available]		02.0710
Polyarthritis
[description not available]		02.0310
Arthritis
Acute or chronic inflammation of JOINTS.		02.0310